Publications

5600 Results

Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153)

Authors
C Kyriakopoulos;Y Chen;R Jeraj;F Duan;J Luo;E Antonarakis;A Tripathi;D Kosoff;R Garje;R Pachynski;R Parikh;A Harzstark;N Adra;B Maughan;Y Zakharia;P Corn;G Liu;M Carducci
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), LBA, Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 17; abstr LBA5000)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8153

Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT Trial

Authors
M Hennessy;C Gatsonis;H Jacene;R Connolly;B Burnette;E Stringer-Reasor;J Romanoff;A Taurone;C O'Sullivan;H Le-Petross;C Lawhn-Heath;V Stearns;A Fowler;S Tang;K Sepulveda;A DeMichelle;D Mankoff;A Wolff
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP Poster;J Clin Oncol 42, 2024 (suppl 16; abstr TPS614)
Year
2024
Research Committee(s)
Breast

Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial

Authors
Y Abdou;J Hoag;W Barlow;J Gralow;F Meric-Berstam;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;A Schott;J Racz;D Tripathy;G Hortobagyi;L Pusztai;P Sharma;K Kalinsky
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract; J Clin Oncol 42, 2024 (suppl 16; abstr 515)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007

Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405

Authors
S Algaze;Y Yang;J Millstein;F Battaglin;S Soni;P Mittal;K Ashouri;P Jayachandran;H Arai;J Ho Lo;W Zhang;L Torres-Gonzalez;A Wong;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 3583)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)

Authors
C Rocha Lima;G Yothers;Puhalla;H Sanoff;D Cohen;K Guthrie;N Henry;P Ganz;S Kopetz;P Lucas;C Blanke;S Jacobs;T Hong;N Wolmark;H Hochster;T George;M Overman
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS3632)
Year
2024
Research Committee(s)
Gastrointestinal

A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma (SWOG S1701)

Authors
A Tsao;M Hsieh;M Koczywas;J Tu;J Riess;T Tanvetyanon;B Ma;Y Zhao;M Redman;M Edelman;D Gandara;K Kelly;J Gray
Journal / Conference
ASCO Annual Meeting (May/31-June 4, 2024, Chicago, IL), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 8110)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S1701

Multi-stakeholder, intentional outreach for improving representative recruitment in Pragmatica–Lung (SWOG S2302)

Authors
D Carrizosa;J Miao;K Reckamp;K Dragnev;P Hesketh;W Iams;B Henick;C Czerlanis;F DeSanto;J Sundstrom;J Johnson;L Gansauer;T Groller;M Redman;R Herbst;J Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 11019)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S2302

Correlations Between First Cycle Toxicity and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
M Othus;S Patel;YK Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2655)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Correlation of Body Mass Index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of Patient (pt) Level Data from SWOG 1216 study

Authors
U Swami;Y Jo;A Narang;M Plets;C Chehade;G Gebrael;S Gupta;Z Myint;C Tangen;P Lara;I Thompson;M Hussain;T Dorff;S Lerner;N Agarwal
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 5081)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S2302, PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab plus Pembrolizumab (PR) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Authors
K Reckamp;M Redman;K Dragnev;W Iams;B Henick;J Miao;D Carrizosa;RS Herbst;J Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS8657)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S2302